Meeting
2017 ASCO Annual Meeting
Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).
Authors
Stergios J. Moschos
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Stergios J. Moschos , Shahneen Kaur Sandhu , Karl D. Lewis , Ryan J. Sullivan , Douglas Buckner Johnson , Yilong Zhang , Erik Rasmussen , Haby A. Henary , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02110355
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2575)
DOI
10.1200/JCO.2017.35.15_suppl.2575
Abstract #
2575
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
First Author: Wen Wee Ma
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers